Program 2025

Program of the 9th AMR Conference

Preliminary overview of sessions. Titles are subject to change. All moderators and speakers to be announced.

Pre-conference meetings

Tuesday, 5 March 2024 | Venue tbd

The pre-conference meetings are not an integral part of the AMR Conference. However, when registering for the conference, you can indicate your interest to participate. The organizers will inform you about the acceptance of your participation shortly before the conference.

09:30 – 15:30

Workshop – Phage Therapy: What’s New and What’s Next?

This interactive workshop aims to delve into the development of a sustainable phage therapy value chain, emphasizing the progress, challenges and opportunities in phage therapy. Sessions will be held on scientific developments, clinical research, and phage manufacturing. Participants will also explore intellectual property strategies and engage in discussions about the global regulatory landscape. In addition, the event will include start-up showcases and an investor panel to discuss funding options and investment strategies. The workshop provides a platform for experts, entrepreneurs, and investors to explore the future of phage therapy. Number of participants will be limited.

Organized by

Fully booked

16:00 – 18:00

Networking meeting

Organized by

Fully booked

Conference Day 1

Tuesday, 25 February 2025 | Congress Center 2nd floor

08:45 – 10:30

BEAM Alliance General Assembly

  

open only to members of the BEAM Alliance

09:00 – 10:30

Pre-conference workshop

 

Title tbd

Jointly organized by

Moderator:
Ursula Theuretzbacher (Center for Anti-Infective Agents)

Speakers:
Malcolm Page (Antibiotic Research): “Integrating TPPs and TCPs in discovery strategies”
Kenneth Bradley
(F. Hoffmann-La Roche Ltd.): “Data driven decision making in antibiotics preclinical research”

11:00 – 12:00

Opening plenary

 

Taking action after renewed political commitment

12:00 – 13:30

Lunch break

13:30 – 14:30

Plenary session

 

Translating AMR clinical needs from local to global

15:00 – 16:00

Parallel sessions

I

Technology corner in diagnostics

II

Remarkable advances in AMR science

III

Pathogen reduction approaches to prevent AMR

16:30 – 17:30

Parallel sessions

I

Financing product development

II

PK/PD approaches to improve the translation of doses to clinic

III

Developing biologics for global purposes

18:00 – 19:30

Start-up pitch

  

Hosted by

10’000 € award sponsored by

Moderator:
Douglas Häggström (INCATE)

Running order of pitching companies:

  1. TabriX (presented by Marc Creus)
  2. BrIgID Biologics (presented by Soumya Palliyil)
  3. BamA Inhibitor (presented by Till Schäberle)
  4. Microplate Dx (presented by Stuart Hannah)
  5. Omnicin Therapeutics (presented by Auke van Heel)
  6. Obulytix (presented by Yves Briers)
  7. Tolka AI Therapeutics (presented by Johan Wikstrom)
  8. Generare (presented by Guillaume Vandenesch)
  9. Theralia AB (presented by Baris Ata Borsa)
  10. Puray (presented by Martin Duffner)
  11. Smartbax (presented by Robert Macsics)

19:30 – 21:30

Evening reception

Conference Day 2

Wednesday, 26 February 2024 | Congress Center 2nd floor

08:30 – 09:30

Plenary session

  

Past failures, future successes

10:00 – 11:00

Parallel sessions

I

Challenges in diagnostic uptakes

II

Technology update

III

Clinical endpoints: fit-for-purpose?

11:30 – 12:30

Plenary session

  

Manufacturing is not only a post-marketing topic

12:30 – 14:00

Lunch break

14:00 – 15:00

Parallel sessions

I

Post-development financing

II

The growing threat of sexually transmitted infections

III

Clinical trials: combining drugs, not problems

15:30 – 16:30

Parallel sessions

I

Making the most of external expertise

II

Reaching the right people with the right drug

III

One Health, climate and innovation

17:00 – 18:00

Closing plenary

  

Communicating on AMR, a simple matter of wording?

and presentation of the poster awards

18:00 – 19:00

Farewell reception

BEAM Alliance program committee

Marc Gitzinger

CEO, BioVersys AG & President, BEAM Alliance

Florence Séjourné

CEO, Aurobac Therapeutics & Treasurer, BEAM Alliance

Deepali Patel

Director of international policy, AMR Action Fund